To avoid ROS anticancer effects, tumor cells can alter their own antioxidant network, including pathways such as nuclear factor erythroid 2/Kelch-like ECH-associated protein 1 (NRF2/KEAP1), GSH and thioredoxin [7,8,11,64,65,66]. This evidence concerns the gene KEAP1 and neoplasm.